Pediatric lymphomas: Recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood

Publisher Website
Google Scholar
Abstract
The importance of staging and classification of pediatric lymphomas is underscored by modern results of clinical trials from many centers and multi-institutional cooperative groups worldwide. Increasing sophistication in immunopathologic classification of the high-grade, aggressive non-Hodgkin's lymphomas (NHLs) characteristic of childhood and adolescence has clarified recognition of a new clinicopathologic entity with predilection for the young, i.e., Ki-1-positive (CD30-positive) anaplastic large-cell lymphoma (ALCL) which accounts for approximately 8–12% of all pediatric NHLs. Even though the majority of ALCLs present with nonlocalized advanced stage (III or IV) disease at diagnosis, five-year survival is in the range of 75–85% from seven reported series of pediatric patients treated with modern multidrug therapy. Further study of this comparatively uncommon entity is needed.